Because much shorter median time from relapse to death remains an urgent unmet need for metastatic TNBC patients, the discovery of FASN as a novel molecular feature directly involved in CCN1- promoted breast cancer metastatic progression might accelerate the incorporation of new generations of FASN inhibitors [61] in the management of metastatic TNBC. Here, FASN is linked to breast carcinoma.